Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer

Colorectal cancer (CRC) is one of the prevalent malignant tumors. This study is aimed at evaluating the mechanism of anlotinib (anlo) on tumor microenvironment (TME) in CRC, and its effects in combination with immune checkpoint inhibitors (ICIs) therapy. Firstly, MC38 and CT26 cells were both expose...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Bixian, Zhang, Shun, Tan, Dan, Yu, Xinbo, Lin, Jianwei, Wang, Mingliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553391/
https://www.ncbi.nlm.nih.gov/pubmed/36238642
http://dx.doi.org/10.1155/2022/8965903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553391/
https://www.ncbi.nlm.nih.gov/pubmed/36238642
http://dx.doi.org/10.1155/2022/8965903

Ejemplares similares